Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Share-based Compensation: 2011-2025

Historic Share-based Compensation for Adma Biologics (ADMA) over the last 12 years, with Sep 2025 value amounting to $5.0 million.

  • Adma Biologics' Share-based Compensation rose 58.76% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.1 million, marking a year-over-year increase of 102.13%. This contributed to the annual value of $13.6 million for FY2024, which is 120.07% up from last year.
  • Latest data reveals that Adma Biologics reported Share-based Compensation of $5.0 million as of Q3 2025, which was up 1.69% from $5.0 million recorded in Q2 2025.
  • Adma Biologics' Share-based Compensation's 5-year high stood at $5.4 million during Q4 2024, with a 5-year trough of $688,274 in Q3 2021.
  • In the last 3 years, Adma Biologics' Share-based Compensation had a median value of $2.9 million in 2024 and averaged $3.1 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first plummeted by 32.37% in 2023, then soared by 211.35% in 2024.
  • Quarterly analysis of 5 years shows Adma Biologics' Share-based Compensation stood at $1.2 million in 2021, then fell by 11.88% to $1.1 million in 2022, then surged by 63.23% to $1.7 million in 2023, then spiked by 211.35% to $5.4 million in 2024, then surged by 58.76% to $5.0 million in 2025.
  • Its last three reported values are $5.0 million in Q3 2025, $5.0 million for Q2 2025, and $4.6 million during Q1 2025.